Comparative Pharmacology
Head-to-head clinical analysis: AZOLID versus FLURBIPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOLID versus FLURBIPROFEN SODIUM.
AZOLID vs FLURBIPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically interfering with peptidoglycan cross-linking.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
2 g intravenously every 6-8 hours; maximum 8 g/day.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 4-8 hours in severe renal impairment (CrCl <30 mL/min)
Clinical Note
moderateFurazolidone + Torasemide
"Furazolidone may increase the hypotensive activities of Torasemide."
Clinical Note
moderateFurazolidone + Travoprost
"Furazolidone may increase the hypotensive activities of Travoprost."
Clinical Note
moderateFurazolidone + Unoprostone
"Furazolidone may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateFurazolidone + Hydrochlorothiazide
"Furazolidone may increase the hypotensive activities of Hydrochlorothiazide."
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Renal (80-90% unchanged), biliary/fecal (10-20%)
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Category C
Category D/X
NSAID
NSAID